Clinical Trial Update: Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM) [Phase 1]

View source ↗

Summary

This Phase 1 study reports on the safety and pharmacokinetics of the investigational agent hOKT3g1 (Ala-Ala) in individuals with Type 1 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• hOKT3g1 (Ala-Ala) (hOKT3g1 (Ala-Ala))

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Diabetes Mellitus, Insulin-Dependent | Phase 1 | Status: COMPLETED